Alkali Therapy in Chronic Kidney Disease

Placebo-controlled Randomized Clinical Trial of Alkali Therapy in Patients With Chronic Kidney Disease

Kidney disease is a common medical condition. Individuals with kidney disease develop a build-up of acid in their blood. This acid can affect their muscles, bones, glucose metabolism and kidneys. The investigators will test alkali treatment, to treat acid build-up, in a randomized placebo-controlled clinical trial to evaluate effects on muscles, bones, glucose metabolism and kidney.

Inclusion Criteria:

• Estimate GFR <= 45 and >15 ml/min/1.73m2
• Age >18

Exclusion Criteria:

• Previous chronic treatment with alkali within the last 3 months (including sodium bicarbonate, calcium carbonate or baking soda)
• bicarbonate level <20 or >25 mEq/L
• New York Heart Association Class III or IV heart failure
• Systolic blood pressure >180 mmHg
• Initiation of ESRD treatment planned within 6 months
• Kidney transplantation
• Treatment with immunosuppressives within the last 3 months